Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs CNS Pharmaceuticals, Inc. (CNSP)

AIM ImmunoTech Inc. and CNS Pharmaceuticals, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and CNS Pharmaceuticals, Inc. are of similar size ($6.1M and $5.9M). CNS Pharmaceuticals, Inc. has the higher net margin (0.00% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, CNS Pharmaceuticals, Inc. leads on 10 and AIM ImmunoTech Inc. on 2.

Valuation

Metric AIM CNSP Biotechnology median
P/E n/m n/m 10.60
P/S 28.83 n/m 9.40
P/B 0.35 1.46 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.70 n/m 0.66
EV/Sales (71.38) n/m 9.02
Earnings yield (2,575.37%) (606.43%) (32.88%)
Free cash flow yield (533.84%) (50.55%) (23.13%)

Profitability

Metric AIM CNSP Biotechnology median
Gross margin (23.16%) 0.00% 68.51%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) (106.62%) (51.96%)
Return on assets (169.28%) (91.64%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM CNSP Biotechnology median
Revenue growth (TTM) (21.49%) — 6.76%
EPS growth (last fiscal year) 72.19% 92.34% 29.88%
Revenue growth, 5-year CAGR (11.60%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM CNSP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 5.86 4.97
Net debt to EBITDA 0.22 0.45 1.01

Dividend

Metric AIM CNSP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AIM CNSP Biotechnology median
Market cap 6.07m 5.86m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack